Awardee OrganizationGENEBACT BIOTECHNOLOGIES, INC.
Description
Abstract Text
DESCRIPTION (provided by applicant): If biological weapons were to be used by a terrorist organization, the public health system would be overwhelmed. The ease of use and delivery along with the apparent widespread availability of biological weapon grade agents could inflict mass civilian casualties anywhere in the world. The best way to combat and defend bioterrorism is to be prepared. Scientists at GeneBact Biotechnologies, Inc. have discovered a new class of Biological Response Modifiers from mammalian serum that we refer to as the Immune Cell Proliferation Factors ("ICPF"). ICPFs are novel lipoproteins that have been shown to have no direct antimicrobial activity, yet retain their ability to abate microbial pathogenesis as presented in a Salmonella typhimurium mouse model and a Pasteurella multocida avian model. ICPFs also show no direct virucidal activity, yet retain the ability to abate viral pathogenesis as presented in a West Nile Virus mouse model and a Parvovirus rat model. ICPFs were also shown to significantly increase levels of the circulating antibodies to Parvovirus in vaccinated rats when the vaccine was adjuvanted with ICPF as compared to a non-adjuvanted vaccine control. The primary objectives of this project are to (i) establish the safety and efficacy of an ICPF formulation for broad spectrum human use in the treatment of bacteremias and viremias, (ii) evaluate the efficacy of an ICPF formulation to provide prophylactic and therapeutic protection against both bacterial and viral infectious agents, and (iii) evaluate the efficacy of ICPF as and adjuvant in vaccines to amplify and expand existing stores of vaccines. The secondary objective of this project is to evaluate the "immunological memory" conferred upon infected patients treated with ICPF. Accomplishing the Tasks as outlined will provide specific benefits to address biowarfare issues in three major areas: 1. Provide a short-term prophylactic agent for use in high-risk populations such as military personnel entering a biological warfare theater of war. 2. Provide an effective therapeutic agent for personnel exposed to a biological warfare agent. 3. Provide an adjuvant to expand and amplify the existing stockpiles of vaccines.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
UEI
Project Start Date
01-August-2003
Project End Date
31-July-2004
Budget Start Date
01-August-2003
Budget End Date
31-July-2004
Project Funding Information for 2003
Total Funding
$133,634
Direct Costs
$127,134
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Allergy and Infectious Diseases
$133,634
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R43AI056595-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R43AI056595-01
Patents
No Patents information available for 1R43AI056595-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R43AI056595-01
Clinical Studies
No Clinical Studies information available for 1R43AI056595-01
News and More
Related News Releases
No news release information available for 1R43AI056595-01
History
No Historical information available for 1R43AI056595-01
Similar Projects
No Similar Projects information available for 1R43AI056595-01